Q-omics provides the consensus-scored MT1G profile across patient tissues and cancer cell-line models. MT1G expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MT1G is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MT1G protein abundance shows 25,936 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where MT1G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT1G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT1G survival associations across molecular data types. MT1G RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT1G RNA expression–survival associations across cancer types. High MT1G expression shows unfavorable associations in KIRC, KICH, UCS, ACC and PAAD, but favorable associations in READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MT1G RNA expression.
This table summarizes MT1G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MT1G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT1G shows lower tumor expression in KIRC, KICH, THCA, KIRP, COAD and LIHC. The KIRC box plot shows higher MT1G RNA expression in normal versus tumor tissue (log2 FC = −6.085, t-test p < 0.001).
This table shows molecular features associated with MT1G in patient tissues and cancer cell lines. In patient samples, MT1G shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MT1G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
